Karyopharm Therapeutics Inc (KPTI) : New Leaf Venture Partners L.l.c. added new position in Karyopharm Therapeutics Inc during the most recent quarter end. The investment management firm now holds 12,226 shares of Karyopharm Therapeutics Inc which is valued at $85,215 , the company said in a statement filed on Aug 15, 2016 with the SEC.Karyopharm Therapeutics Inc makes up approximately 0.07% of New Leaf Venture Partners L.l.c.’s portfolio.
Other Hedge Funds, Including , Schwab Charles Investment Management Inc boosted its stake in KPTI in the latest quarter, The investment management firm added 882 additional shares and now holds a total of 60,498 shares of Karyopharm Therapeutics Inc which is valued at $421,671.Teachers Advisors Inc reduced its stake in KPTI by selling 515 shares or 1.41% in the most recent quarter. The Hedge Fund company now holds 36,017 shares of KPTI which is valued at $251,038. Tfs Capital added KPTI to its portfolio by purchasing 49,883 company shares during the most recent quarter which is valued at $347,685. Karyopharm Therapeutics Inc makes up approx 0.06% of Tfs Capital’s portfolio.Vanguard Group Inc boosted its stake in KPTI in the latest quarter, The investment management firm added 127,714 additional shares and now holds a total of 816,444 shares of Karyopharm Therapeutics Inc which is valued at $5,690,615.Blackrock Investment Management boosted its stake in KPTI in the latest quarter, The investment management firm added 11,865 additional shares and now holds a total of 93,568 shares of Karyopharm Therapeutics Inc which is valued at $652,169.
Karyopharm Therapeutics Inc opened for trading at $10.05 and hit $11.41 on the upside on Thursday, eventually ending the session at $11.1, with a gain of 11.56% or 1.15 points. The heightened volatility saw the trading volume jump to 13,70,306 shares. Company has a market cap of $399 M.
Many Wall Street Analysts have commented on Karyopharm Therapeutics Inc. Karyopharm Therapeutics Inc was Upgraded by Jefferies to ” Buy” on Aug 30, 2016. H.C. Wainwright Initiated Karyopharm Therapeutics Inc on Aug 18, 2016 to “Buy”, Price Target of the shares are set at $15.Robert W. Baird Initiated Karyopharm Therapeutics Inc on Jun 28, 2016 to “Outperform”, Price Target of the shares are set at $16.
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibits the nuclear export protein XPO1. The Company is seeking the regulatory approval and commercialization of its lead drug candidate selinexor (KPT-330) as a single orally administered agent in cancer indications with unmet clinical need initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.